marijuana rescheduling is on hold after a recent federal hearing, and Connecticut cannabis operators say the outcome will change day-to-day business risks but not immediately alter state rules.
Federal agencies held a public proceeding that examined whether cannabis should move from Schedule I under the Controlled Substances Act to a lower schedule. The Department of Health and Human Services (HHS) provides medical and scientific recommendations to the Drug Enforcement Administration (DEA), and the DEA then decides whether to reschedule. Industry leaders in Connecticut say the hearing prompted questions about banking access, federal tax treatment, research pathways and timelines.
Current status: under federal law, cannabis remains a Schedule I substance. That classification bars standard prescriptions, restricts federal research approvals and underpins the IRS code section 280E, which prevents businesses selling federally controlled substances from claiming business deductions. Rescheduling to Schedule III would remove the Schedule I status and could reopen specific federal avenues: physicians could prescribe some products, some research requirements would ease, and tax accountants could apply ordinary deductions for allowable business expenses.
What Connecticut operators say: cultivators, retailers and service providers in Connecticut describe the hearing as a sign of change but not a trigger for immediate operational shifts. Retail managers report that state licensing, product testing and local ordinances still control daily operations. A retail store manager in Hartford said staff are preparing policies for safer cash handling and possible banking adoption, but are not changing inventory, staffing or pricing because state law remains the operative framework.
Banking and finance: one direct effect often discussed is banking access. Most federally insured banks and credit unions avoid cannabis businesses because of the federal schedule. Rescheduling could reduce legal exposure for financial institutions and therefore increase the likelihood that banks will offer accounts, payment processing and loans to cannabis operators. Connecticut operators say access to loans and commercial lines of credit would let them shift from cash-heavy models and could lower borrowing costs. Law firms and bankers warn, however, that rescheduling would not instantly force banks to onboard accounts; compliance programs, risk assessments, and internal policy changes would likely take months to implement.
Taxes and 280E: accountants emphasize a measurable tax impact if rescheduling moves cannabis out of Schedule I or II. Section 280E of the Internal Revenue Code disallows deductions for businesses trafficking in controlled substances listed in Schedule I or II. If cannabis moves to Schedule III, eligible businesses could deduct ordinary expenses like payroll, rent and utilities. Tax professionals estimate that affected businesses could see effective federal tax liabilities drop by multiple percentage points, depending on profit margins and state-level taxes. Businesses say they are working with accountants to model scenarios, but none plan immediate tax filings based on the hearing alone.
Research and product development: HHS advisors and researchers told the hearing panel that rescheduling would expand FDA-regulated clinical trials and lower administrative barriers for university research. Connecticut universities and clinical researchers could apply more easily for federal grants and institutional review board approvals to study cannabinoids. Several small manufacturers in Connecticut told reporters they would accelerate product development plans if rescheduling shortened the timeline for clinical trials and eventual FDA approvals.
Limitations and remaining hurdles: rescheduling does not legalize interstate cannabis commerce or automatically clear state-level prohibitions. Federal rescheduling would change criminal and regulatory exposure but would leave intact Connecticut’s own regulatory framework for licensing, testing and sales. Law enforcement officials in Connecticut said they expect state criminal statutes and municipal rules to remain in force and that any operational shift would evolve over months or years.
Timeline and uncertainty: industry advisers and legal experts say the DEA decision could take months to more than a year after the hearing. If the DEA issues a rescheduling order, implementing regulations and IRS guidance would follow. Banks, insurers and federal agencies would then adjust policies. Connecticut operators describe the period as a planning window: they are updating compliance manuals, training staff on potential banking transitions, and consulting tax professionals to prepare for possible deduction eligibility.
Concrete planning examples: one cultivation company reported updating inventory controls and point-of-sale systems to enable bank reconciliations, anticipating a switch from cash deposits to electronic payments. A dispensary chain said it is lining up letters of credit that could convert to bank lines if institutions open accounts. Research labs at two Connecticut colleges told industry groups they were drafting trial protocols that could start quickly if federal approvals arrive.
What to watch next: operators will monitor three measurable items: (1) the DEA’s formal notice and decision timeline; (2) any interim guidance from the IRS about 280E treatment; and (3) bank and insurer announcements about program rollouts for cannabis clients. Each of these steps includes specific deadlines and public statements that industry sources can cite when changing business plans.
Bottom line: Connecticut cannabis businesses view the federal hearing as an important regulatory checkpoint that could change legal and financial dynamics. They are avoiding immediate operational changes while preparing concrete plans that would activate if federal agencies follow through on rescheduling. For now, state licensing, testing requirements and municipal rules remain the binding constraints on day-to-day business.
